## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Baker et al.

Serial No.: Not yet assigned

Filed: Herewith

For: Secreted and Transmembrane

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Encoding the Same

Polypeptides and Nucleic Acids

Sir:

Prior to substantive examination of the above captioned patent application (which is filed herewith), and for calculation of the proper filing fee, Applicants respectfully request that the following amendments be entered.

Filed: Herewith

## In the claims:

Please cancel Claims 1-21 without prejudice or disclaimer.

Please add new Claims 22-41 as follows.

-22. (New) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
- 23. (New) The isolated nucleic acid of Claim 22 having at least 85% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;

Filed: Herewith

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);

- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
- 24. (New) The isolated nucleic acid of Claim 22 having at least 90% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Filed: Herewith

25. (New) The isolated nucleic acid of Claim 22 having at least 95% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
- 26. (New) The isolated nucleic acid of Claim 22 having at least 99% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;

Filed: Herewith

(e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);

- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
  - 27. (New) An isolated nucleic acid comprising:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
- 28. (New) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83).

HESC. CEPAPEC

Serial No.: Not yet assigned

Filed: Herewith

29. (New) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

30. (New) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83).

31. (New) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide.

32. (New) The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82).

33. (New) The isolated nucleic acid of Claim 27 comprising the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82).

34. (New) The isolated nucleic acid of Claim 27 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

35. (New) An isolated nucleic acid that hybridizes to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;

Filed: Herewith

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83);

- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO:83), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 31 (SEQ ID NO:82); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.
- 36. (New) The isolated nucleic acid of Claim 35, wherein said hybridization occurs under stringent conditions.
- 37. (New) The isolated nucleic acid of Claim 35 which is at least 10 nucleotides in length.
  - 38. (New) A vector comprising the nucleic acid of Claim 22.
- 39. (New) The vector of Claim 38, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
  - 40. (New) A host cell comprising the vector of Claim 38.
- 41. (New) The host cell of Claim 40, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.--

Filed: Herewith

Applicants respectfully request entry of these new claims for prosecution in this application. The Examiner is invited to contact the undersigned at (650) 225-4563 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

Elizabeth M. Barnes, Ph.D.

Reg. No. 35,059

Telephone: (650) 225-4563

PATENT TRADEMARK OFFICE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Group Art Unit: Not yet assigned

Baker et al.

Examiner: Not yet assigned

Serial No.: Not yet assigned

Filed: Herewith

For:

Secreted and Transmembrane Polypeptides and Nucleic Acids

Encoding the Same

## REQUEST TO USE COMPUTER READABLE FORM OF SEQUENCE LISTING FROM PARENT APPLICATION PURSUANT TO 37 C.F.R. § 1.821 (e)

**Assistant Commissioner of Patents** Washington, D.C. 20231

Sir:

The patent application filed herewith is a continuing application of currently pending application Serial No. 09/866,028, filed on May 25, 2001. The Sequence Listings in (a) the herewith filed patent application and (2) currently pending patent application Serial No.09/866,028, filed on May 25, 2001, are identical. Therefore, pursuant to 37 C.F.R. § 1.821(e), Applicants respectfully request that the compliant computer readable form of the Sequence Listing filed on May 25, 2001 in parent application Serial No. 09/866,028 be used as the computer readable form for the herewith filed patent application. The paper copy of the Sequence Listing submitted herewith

Filed: Herewith

PATENT TRADEMARK OFFICE

is identical to that on the compliant computer readable form of the Sequence Listing filed on May 25, 2001 in parent application Serial No. 09/866,028.

Respectfully submitted,

GENENTECH, INC.

Elizabeth M. Barnes, Ph.D.

Reg. No. 35,059

Telephone: (650) 225-4563

-2-